---
schema_version: "secwatch.filing_event.v1"
accession: "0001816590-26-000043"
form_type: "8-K"
ticker: "CMPS"
cik: "0001816590"
company_name: "COMPASS Pathways plc"
filed_at: "2026-05-13T10:30:53+00:00"
generated_at: "2026-05-13T10:36:40.137366+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Q1 net income $91.2M on warrant gain; cash $466M; FDA grants COMP360 rolling NDA submission

## Summary
- FDA granted Compass NDA rolling submission for COMP360 in TRD based on positive Phase 3 data; CNPV awarded.
- Net income $91.2M ($0.71 basic EPS) vs net loss $17.9M in Q1 2025; non-cash warrant gain of $130.9M.
- Cash $466.0M at Mar 31 2026 (from $149.6M at Dec 31 2025); debt $50.5M (from $31.6M).
- R&D expenses $26.5M (down from $30.9M); G&A $16.4M (down from $18.7M).
- Final NDA submission on track for Q4 2026; 26-week COMP006 data expected early Q3 2026.

## SEC filing metadata
- accession: 0001816590-26-000043
- form_type: 8-K
- ticker: CMPS
- cik: 0001816590
- company_name: COMPASS Pathways plc
- filed_at: 2026-05-13T10:30:53+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1816590/000181659026000043/0001816590-26-000043-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1816590/000181659026000043/cmps-20260513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001816590-26-000043
- JSON: https://secwatch.observer/filing/0001816590-26-000043.json
- Plain text: https://secwatch.observer/filing/0001816590-26-000043.txt

## Key facts
- Earnings Releases
  COMPASS Pathways plc reported for the three months ended March 31, 2026 results: net income $91.2 million, or $0.71 net income per share (basic) and $0.30 net loss per share (diluted), EPS $0.71 net income per share (basic) and $0.30 net loss per share (diluted). Guidance reaffirmed.
  - Period: for the three months ended March 31, 2026
  - Net income: $91.2 million, or $0.71 net income per share (basic) and $0.30 net loss per share (diluted)
  - EPS: $0.71 net income per share (basic) and $0.30 net loss per share (diluted)
  - Guidance: reaffirmed
  - Result: reported results
  source text: Compass Pathways plc (the “Company”) issued a press release announcing the Company's financial results for the three months ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1816590/000181659026000043/0001816590-26-000043-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.